Arcus Biosciences Inc.

06/12/2026 | Press release | Distributed by Public on 06/12/2026 14:13

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders
On June 11, 2026, Arcus Biosciences, Inc. (the "Company") held its annual meeting of stockholders. The results of the stockholder votes on each proposal brought before the Annual Meeting is as follows:
Proposal 1: The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified:
Nominee Votes For Votes Withheld Broker Non-Votes
Dietmar Berger, M.D., Ph.D. 85,949,508 18,338,022 13,573,227
David Lacey, M.D. 85,974,583 18,312,947 13,573,227
Nicole Lambert 92,653,341 11,634,189 13,573,227
Johanna Mercier 85,941,754 18,345,776 13,573,227
Proposal 2: The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026:
Votes For Votes Against Abstentions
112,905,582 4,767,430 187,745
Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement:
Votes For Votes Against Abstentions Broker Non-Votes
94,920,421 9,337,368 29,741 13,573,227
Arcus Biosciences Inc. published this content on June 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 12, 2026 at 20:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]